Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: Involvement of PPAR-α

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Esposito, Emanuela ^a   Rinaldi, Barbara ^b   Mazzon, Emanuela ^a,c   Donniacuo, Maria ^b   Impellizzeri, Daniela ^a   Paterniti, Irene ^a   Capuano, Annalisa ^b   Bramanti, Placido ^a,c   Cuzzocrea, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Inflammation; PPAR ; SCI; Simvastatin

Indexed keywords

3 NITROTYROSINE; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN BAX; PROTEIN BCL 2; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MIGRATION INHIBITION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR GENE; RECEPTOR UPREGULATION; WILD TYPE;

EID: 84860209867     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-81     Document Type: Article

References (77)

1. Bartholdi D, Schwab ME. Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. Brain Res 1995, 672:177-186. 10.1016/0006-8993(94)01410-J, 7749740.
2. Kaltschmidt B, Baeuerle PA, Kaltschmidt C. Potential involvement of the transcription factor NF-kappa B in neurological disorders. Mol Aspects Med 1993, 14:171-190. 10.1016/0098-2997(93)90004-W, 8264332.
3. Blight AR. Macrophages and inflammatory damage in spinal cord injury. J Neurotrauma 1992, 9(Suppl 1):S83-91.
4. Samadikuchaksaraei A. An overview of tissue engineering approaches for management of spinal cord injuries. J Neuroengineering Rehabil 2007, 4:15.
5. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000, 101:207-213.
6. Alvarez de Sotomayor M, Vega S, Mingorance C, Marhuenda E, Herrera MD. Effects of HMG-CoA reductase inhibition by simvastatin on vascular dysfunction induced by lipopolysaccharide in rats. Pharmacology 2008, 82:89-96. 10.1159/000135629, 18509252.
7. Fraunberger P, Grone E, Grone HJ, Walli AK. Simvastatin reduces endotoxin-induced nuclear factor kappaB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol. Shock 2009, 32:159-163. 10.1097/SHK.0b013e318193c514, 19008785.
8. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007, 59:483-499.
9. Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, Antunes-Rodrigues J. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 2004, 21:271-275. 10.1097/10.shk.0000115756.74059.ce, 14770041.
10. Stuve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003, 16:393-401. 10.1097/00019052-200306000-00021, 12858078.
11. Maggard MA, Ke B, Wang T, Kaldas F, Seu P, Busuttil RW, Imagawa DK. Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation 1998, 65:149-155.
12. Crisby M. Modulation of the inflammatory process by statins. Drugs Today (Barc) 2003, 39:137-143.
13. Umesono K, Giguere V, Glass CK, Rosenfeld MG, Evans RM. Retinoic acid and thyroid hormone induce gene expression through a common responsive element. Nature 1988, 336:262-265. 10.1038/336262a0, 2848197.
14. Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000, 21:469-474. 10.1016/S0165-6147(00)01559-5, 11121836.
15. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688. 10.1210/er.20.5.649, 10529898.
16. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005, 51:85-94. 10.1016/j.phrs.2004.07.012, 15629253.
17. Wayman N, McDonald MC, Thompson AS, Threadgill MD, Thiemermann C. 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur J Pharmacol 2001, 430:93-100. 10.1016/S0014-2999(01)01359-0, 11698068.
18. Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid × receptors in the adult rat CNS. Neuroscience 2004, 123:131-145. 10.1016/j.neuroscience.2003.08.064, 14667448.
19. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993, 32:5598-5604. 10.1021/bi00072a015, 7684926.
20. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 2003, 108:2393-2399. 10.1161/01.CIR.0000093187.42015.6C, 14557369.
21. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 2006, 110:371-385. 10.1016/j.pharmthera.2005.08.007, 16168490.
22. Yang Q, Xie Y, Alexson SE, Nelson BD, DePierre JW. Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem Pharmacol 2002, 63:1893-1900. 10.1016/S0006-2952(02)00923-1, 12034374.
23. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Centorrino T, Caputi AP. Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Lab Invest 2004, 84:1643-1654. 10.1038/labinvest.3700185, 15492755.
24. Genovese T, Esposito E, Mazzon E, Di Paola R, Muia C, Meli R, Bramanti P, Cuzzocrea S. Effect of cyclopentanone prostaglandin 15-deoxy-delta12,14PGJ2 on early functional recovery from experimental spinal cord injury. Shock 2008, 30:142-152.
25. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048-32054. 10.1074/jbc.274.45.32048, 10542237.
26. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000, 275:36703-36707. 10.1074/jbc.M004045200, 10980195.
27. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:323-330.
28. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 2006, 98:361-369. 10.1161/01.RES.0000202706.70992.95, 16397146.
29. Rinaldi B, Donniacuo M, Esposito E, Capuano A, Sodano L, Mazzon E, Di Palma D, Paterniti I, Cuzzocrea S, Rossi F. PPARalpha mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. Br J Pharmacol 163:609-623.
30. Zhang S, Rahman M, Zhang S, Qi Z, Thorlacius H. Simvastatin antagonizes CD40L secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in abdominal sepsis. J Leukoc Biol 89:735-742.
31. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985, 14:157-167. 10.1016/0160-5402(85)90029-4, 2997548.
32. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 2006, 23:635-659. 10.1089/neu.2006.23.635, 16689667.
33. Genovese T, Mazzon E, Mariotto S, Menegazzi M, Cardali S, Conti A, Suzuki H, Bramanti P, Cuzzocrea S. Modulation of nitric oxide homeostasis in a mouse model of spinal cord injury. J Neurosurg Spine 2006, 4:145-153. 10.3171/spi.2006.4.2.145, 16506482.
34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
35. Genovese T, Mazzon E, Di Paola R, Cannavo G, Muia C, Bramanti P, Cuzzocrea S. Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. Exp Neurol 2005, 194:267-278. 10.1016/j.expneurol.2005.03.003, 15899263.
36. Rinaldi B, Donniacuo M, Esposito E, Capuano A, Sodano L, Mazzon E, Di Palma D, Paterniti I, Cuzzocrea S, Rossi F. PPARalpha mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. Br J Pharmacol 2011,
37. Kimura T, Mogi C, Tomura H, Kuwabara A, Im DS, Sato K, Kurose H, Murakami M, Okajima F. Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol 2008, 181:7332-7340.
38. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683. 10.1146/annurev.immunol.14.1.649, 8717528.
39. Beg AA, Finco TS, Nantermet PV, Baldwin AS. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol 1993, 13:3301-3310. 359784, 8497253.
40. Di Marco B, Massetti M, Bruscoli S, Macchiarulo A, Di Virgilio R, Velardi E, Donato V, Migliorati G, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ)/NF-kappaB interaction: role of GILZ homo-dimerization and C-terminal domain. Nucleic Acids Res 2007, 35:517-528. 1802615, 17169985.
41. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005, 30:43-52. 10.1016/j.tibs.2004.11.009, 15653325.
42. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004, 4:451-464. 10.1016/j.spinee.2003.07.007, 15246307.
43. Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L. Acute inflammatory response in spinal cord following impact injury. Exp Neurol 1998, 151:77-88. 10.1006/exnr.1998.6785, 9582256.
44. Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, Pasquale-Styles M, Dietrich WD, Weaver LC. The cellular inflammatory response in human spinal cords after injury. Brain 2006, 129:3249-3269. 10.1093/brain/awl296, 17071951.
45. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004, 94:1168-1178. 10.1161/01.RES.0000127122.22685.0A, 15142970.
46. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169:453-459. 10.1677/joe.0.1690453, 11375115.
47. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 2004, 172:5790-5798.
48. Bao F, DeWitt DS, Prough DS, Liu D. Peroxynitrite generated in the rat spinal cord induces oxidation and nitration of proteins: reduction by Mn (III) tetrakis (4-benzoic acid) porphyrin. J Neurosci Res 2003, 71:220-227. 10.1002/jnr.10481, 12503084.
49. Bao F, Liu D. Peroxynitrite generated in the rat spinal cord induces apoptotic cell death and activates caspase-3. Neuroscience 2003, 116:59-70. 10.1016/S0306-4522(02)00571-7, 12535938.
50. Liu D, Bao F, Prough DS, Dewitt DS. Peroxynitrite generated at the level produced by spinal cord injury induces peroxidation of membrane phospholipids in normal rat cord: reduction by a metalloporphyrin. J Neurotrauma 2005, 22:1123-1133. 10.1089/neu.2005.22.1123, 16238488.
51. Scott GS, Szabo C, Hooper DC. Poly(ADP-ribose) polymerase activity contributes to peroxynitrite-induced spinal cord neuronal cell death in vitro. J Neurotrauma 2004, 21:1255-1263.
52. Xiong Y, Rabchevsky AG, Hall ED. Role of peroxynitrite in secondary oxidative damage after spinal cord injury. J Neurochem 2007, 100:639-649. 10.1111/j.1471-4159.2006.04312.x, 17181549.
53. Xu J, Kim GM, Chen S, Yan P, Ahmed SH, Ku G, Beckman JS, Xu XM, Hsu CY. iNOS and nitrotyrosine expression after spinal cord injury. J Neurotrauma 2001, 18:523-532. 10.1089/089771501300227323, 11393255.
54. Bolanos JP, Heales SJ, Land JM, Clark JB. Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture. J Neurochem 1995, 64:1965-1972.
55. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003, 25:295-311. 10.1007/s00726-003-0018-8, 14661092.
56. Sharma SS, Dhar A, Kaundal RK. FeTPPS protects against global cerebral ischemic-reperfusion injury in gerbils. Pharmacol Res 2007, 55:335-342. 10.1016/j.phrs.2007.01.002, 17292620.
57. Dhar A, Kaundal RK, Sharma SS. Neuroprotective effects of FeTMPyP: a peroxynitrite decomposition catalyst in global cerebral ischemia model in gerbils. Pharmacol Res 2006, 54:311-316. 10.1016/j.phrs.2006.06.009, 16877004.
58. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 2003, 140-141:105-112.
59. Haddad JJ. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002, 14:879-897. 10.1016/S0898-6568(02)00053-0, 12220615.
60. Crisafulli C, Cuzzocrea S. The role endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages. Shock 2008, 32(1):62-73.
61. Crisafulli C, Bruscoli S, Esposito E, Mazzon E, Di Paola R, Genovese T, Bramanti P, Migliorati G, Cuzzocrea S. PPAR-alpha contributes to the anti-inflammatory activity of 17beta-estradiol. J Pharmacol Exp Ther 2009, 331:796-807. 10.1124/jpet.109.156646, 19755663.
62. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719. 10.1161/hq1101.098486, 11701455.
63. Benani A, Kremarik-Bouillaud P, Bianchi A, Netter P, Minn A, Dauca M. Evidence for the presence of both peroxisome proliferator-activated receptors alpha and beta in the rat spinal cord. J Chem Neuroanat 2003, 25:29-38. 10.1016/S0891-0618(02)00093-5, 12573457.
64. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996, 384:39-43. 10.1038/384039a0, 8900274.
65. Gonzalez FJ. Recent update on the PPAR alpha-null mouse. Biochimie 1997, 79:139-144. 10.1016/S0300-9084(97)81506-4, 9209711.
66. Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW, Shi YF. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000, 88:333-347. 10.1016/S0163-7258(00)00096-6, 11337030.
67. Dosreis GA, Borges VM, Zin WA. The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med 2004, 8:285-293. 10.1111/j.1582-4934.2004.tb00318.x, 15491504.
68. Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Esposito E, Bramanti P, Cuzzocrea S. TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. Shock 2008, 29:32-41.
69. Bauer MK, Vogt M, Los M, Siegel J, Wesselborg S, Schulze-Osthoff K. Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. J Biol Chem 1998, 273:8048-8055. 10.1074/jbc.273.14.8048, 9525905.
70. Siniscalco D, Fuccio C, Giordano C, Ferraraccio F, Palazzo E, Luongo L, Rossi F, Roth KA, Maione S, de Novellis V. Role of reactive oxygen species and spinal cord apoptotic genes in the development of neuropathic pain. Pharmacol Res 2007, 55:158-166. 10.1016/j.phrs.2006.11.009, 17207636.
71. Xu W, Chi L, Xu R, Ke Y, Luo C, Cai J, Qiu M, Gozal D, Liu R. Increased production of reactive oxygen species contributes to motor neuron death in a compression mouse model of spinal cord injury. Spinal Cord 2005, 43:204-213. 10.1038/sj.sc.3101674, 15520836.
72. Beattie MS, Hermann GE, Rogers RC, Bresnahan JC. Cell death in models of spinal cord injury. Prog Brain Res 2002, 137:37-47.
73. Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995, 374:733-736. 10.1038/374733a0, 7715730.
74. Roberts RA, James NH, Woodyatt NJ, Macdonald N, Tugwood JD. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis 1998, 19:43-48. 10.1093/carcin/19.1.43, 9472691.
75. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009, 119:131-138. 10.1161/CIRCULATIONAHA.108.813311, 2745913, 19075102.
76. Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009, 29:706-711. 10.1161/ATVBAHA.108.183160, 19150877.
77. Gao F, Linhartova L, Johnston AM, Thickett DR. Statins and sepsis. Br J Anaesth 2008, 100:288-298. 10.1093/bja/aem406, 18276651.